Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01603017
Recruitment Status : Completed
First Posted : May 21, 2012
Last Update Posted : May 21, 2012
Information provided by (Responsible Party):
S Barker, NHS Grampian

May 15, 2012
May 21, 2012
May 21, 2012
September 2007
December 2008   (Final data collection date for primary outcome measure)
Oxford Knee Score [ Time Frame: 12 weeks ]
Patient administered validated questions
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis
Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis: A Double Blind Ranomised Controlled Trial

Nuclear Magnetic Resonance Therapy (NMRT) is gaining as a novel mode of therapy in osteoarthrosis. A prospective double blind randomised study of 100 patients was conducted to investigate efficacy of NMRT in the treatment of mild to moderate osteoarthrosis (OA) of the knee joint.

The null hypothesis was that there is no benefit of NMRT over placebo in mild to moderate oteoarthosis of the knee.

This study was approved by the Regional Ethics Committee. Patients were recruited from referrals made by General Practitioners to a single Orthopaedic Outpatient Department between October 2007 and February 2008. The study was a prospective placebo controlled, double blind randomised mono centric study with a follow up period of 6 months.

All potential trial participants demonstrated symptomatic mild to moderate OA of the knee joint diagnosed by an experienced consultant orthopaedic surgeon. Radiographic evidence was gathered by means of standard clinical standing antero-posterior and lateral radiographs of the knee.

Baseline assessment included :

  1. clinical examination
  2. active Range of movement
  3. plain radiographs
  4. WOMAC osteoarthritis index
  5. Oxford Knee Score (OKS)
  6. Severity of pain VAS.
  7. Strength and frequency of any painkillers taken.
  8. Phyasiotherapy Study design was directed at use of NMRT in a clinical setting. It was therefore considered valid to not restrict the use of the pain killers and physiotherapy. Positional Magnetic Resonance Imaging (pMRI) scan of the knee joint was undertaken.

Randomisation was carried out by means of visually identical computer chip cards numbered from 1 to 100 which had been independently programmed by the manufacturer. Thus, half of the computer chip cards (n=50) were programmed to activate the magnetic fields (= treatment group) and remaining half (n=50) were programmed not to activate magnetic fields (=placebo group) of the device. The research team and patients were blinded to the programmed activity of the cards. The magnetic resonance indicator LED lamp on the device was disabled by the manufacturer to ensure that the operator and patients were blinded to the therapy status. Every patient entering the study was asked to choose a numbered card from those available, and this card was then used to operate the device for that specific patient for all five sessions of NMRT.

The study used the manufacturer's clinical recommendation for therapy. Patients were subjected to one-hour sessions of NMRT (or placebo) on five consecutive days, giving a total of five hours of NMRT (or placebo). This was given on an outpatient basis.

The device is made up of twelve independently controlled coil systems that are spaced orthogonally. These are designed to produce a 3-dimensional therapy field. Along with a separately generated permanent magnetic field, the 3-dimensional therapy field forms a nuclear resonance field in the center of the coil system. The desired dose of NMRT is achieved with the help of MBST® - Treatment software, which is controlled by a computer chip card. The device can generate a magnetic field of 3.0 mT (typical) and maximum of 10 mT extending up to 30 cm around the device.

Patients were called for review at 1 week (1w), 1 month (1m), 3 months (3m) and 6 months (6m) when clinical examination, WOMAC osteoarthritis index and OKS were repeated. They were also asked to record VAS and details of painkillers taken during the week before each review. Due to the lack of recognised analgesia equivalencies, the quantity of pain killers taken were graded with reference to the amount and frequency taken at baseline - less than baseline was graded as 1, same as baseline was graded as 2 and more than baseline was graded as 3.

Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Device: MRI therapy
    5 treatments with magnetic field delivered to knee (n=50)
    Other Names:
    • MBST-01, Version KSRT, Type 300 KSRT,
    • Serial Nos. 12100411 and 23490318,
    • manufactured by AD Elektronik GmbH, Wetzlar, Germany
  • Device: MRI therapy (off)
    5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
    Other Names:
    • MBST-01, Version KSRT, Type 300 KSRT,
    • Serial Nos. 12100411 and 23490318,
    • manufactured by AD Elektronik GmbH, Wetzlar, Germany
  • Placebo Comparator: Placebo - no therapy
    Patients who were blinded but did not receive therapy
    Intervention: Device: MRI therapy (off)
  • Experimental: MRI therapy
    Patients receiving MRI therapy but blinded to it
    Intervention: Device: MRI therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Osteoarthrosis of the knee(s)
  • Moderately severe (grade 1-2)

Exclusion Criteria:

  • Prior knee surgery
  • Implanted metallic devices
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
S Barker, NHS Grampian
NHS Grampian
Not Provided
Principal Investigator: Simon L Barker, MD NHS Grampian
NHS Grampian
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP